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Introduction
Public awareness and widespread screening for
prostate cancer has led to an increased detection of
localized and potentially curable tumor stages [1].
Whereas radical prostatectomy results in disease-spe-
cific survival rates of approximately 90% in organ-con-
fined disease [2], the survival rates are unsatisfactory
when the disease has spread outside the prostate. In a
multicentric trial with 298 stage cT3 patients treated by
pelvic lymphadenectomy with or without radical
prostatectomy, the disease-specific 10-year survival
was only 57% [3]. Similarly unfavorable results were
observed after radiotherapy alone for locally advanced
prostate cancer [4]. Therefore, considerable efforts
have been focussed on the development of adjuvant
treatment modalities to improve these results. This
review will discuss the current knowledge and ongoing
studies in the field of adjuvant treatment of prostate
cancer.
Rationale for Adjuvant Treatment
Adjuvant treatment is given after the resection or
destruction of all macroscopic tumor tissue to prevent
progression of suspected microscopic residual disease.
An appropriate adjuvant therapy requires the avail-
ability of effective drugs without severe and irre-
versible side effects and the ability to identify patients
who are at high risk of tumor progression. The tradi-
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tional forms of hormonal manipulation in prostate can-
cer, i.e. orchiectomy and estrogen treatment, suffer
from considerable disadvantages limiting their suit-
ability in the adjuvant setting. The application of estro-
gens has been shown to be accompanied by severe car-
diovascular side effects [5]. Orchiectomy, on the other
hand, is an irreversible measure followed by impotence
and, in the long run, by osteoporosis and the risk of
pathologic fractures [6]. During the last decades, new
ways of hormonal deprivation (LHRH analogues,
antiandrogens) have been developed which allow
revers-ible treatment with fewer side effects and have
opened new perspectives in the adjuvant treatment of
prostate cancer.
Prognostic Factors in Localized Prostate Cancer
Not all patients can be expected to benefit from
adjuvant treatment. Especially in patients with organ-
confined disease, the general application of adjuvant
therapy would expose a large majority to unnecessary
side effects and considerably increase treatment costs.
It is essential to identify subgroups of patients with
unfavorable tumor characteristics who are at a high risk
of failure after treatment with curative intent. In a
study with 721 patients with clinically organ-confined
prostate cancer, Epstein et al. [7] identified the Gleason
score in the prostatectomy specimen, the extent of cap-
sular penetration and the status of the surgical margins
as independent prognostic factors. Besides these pa-
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rameters, Kupelian et al. [8] showed that the preopera-
tive prostate-specific antigen (PSA) value is the most
reliable clinical predictor of biochemical failure after
radical prostatectomy. While in patients with a preop-
erative PSA value of 4 ng/ml the 10-year progression
risk is only 13%, it is 72% in patients with a PSA value
of 20 ng/ml [8]. Nevertheless, further research is
needed in the field of prognostic markers in early
prostate cancer, since the estimation of the risk of pro-
gression is still not adequate for individual patients [9].
Due to this prognostic uncertainty, current studies in
early prostate cancer need a large number of patients
and long follow-up periods to assess the efficacy of
adjuvant treatment.
Early versus 
Deferred Hormonal Treatment
Although about 80% of prostate cancers are initially 
responsive to hormonal manipulation, most non-
curatively treated patients develop hormone-refractory
disease during hormonal therapy within 12–18 months.
Since the first description of the effect of androgen
deprivation on prostate cancer [10–12], great efforts
have been made to establish new forms of hormonal
treatment and to increase the efficacy of this therapy.
Nevertheless, the survival rates of non-curatively treat-
ed prostate cancer patients have not increased during
this time. Furthermore, conclusive evidence for a gen-
eral survival benefit of hormonal treatment is still lack-
ing today.
Zincke et al. [13] found that immediate hormonal
treatment significantly delayed the time to progression
in stage D1 tumors after radical prostatectomy. A sur-
vival advantage, however, was only observed for pa-
tients with diploid tumors. 
In a randomized study of 938 patients with locally
advanced or asymptomatic metastatic prostate cancer
[14], there was a significant survival advantage for
those who were treated with immediate hormonal ther-
apy. However, this study has been criticized because
some patients in the delayed arm died without receiv-
ing hormonal therapy thus diminishing the reliability
of the data. Nevertheless, there were some important
results in this trial in favor of immediate therapy. Some
severe complications attributed to progressive disease
occurred significantly less often in the immediate treat-
ment arm (spinal cord compression, ureteral obstruc-
tion, extra-skeletal metastatic metastases).
Recently, a randomized trial (n = 98, median follow-
up 7.1 years) comparing immediate hormonal therapy
with observation in prostate cancer patients with min-
imal lymph node disease treated by radical prostatec-
tomy and pelvic lymph node dissection showed a sig-
nificantly reduced risk of tumor recurrence and death
of prostate cancer in the arm treated immediately [15].
Other studies, however, have yielded different results.
An ongoing EORTC study with 302 stage D1 patients
who did not undergo radical prostatectomy showed no
advantage for immediate treatment concerning cancer-
specific survival after a median follow-up of 6 years
[16]. A series from the Mayo Clinic demonstrated a
survival advantage only for diploid tumors and only
after a follow-up of 10 years [17]. These differences
brought up several questions concerning possible bi-
ases which possibly influenced the results of the trial by
Messing et al. [16]. Concern has been expressed that
factors such as the small size of the study and the
absence of a correlation between histologic grade and
survival could create imbalances that would account
for the surprisingly large difference in survival within a
relatively short period of time [17]. In conclusion,
although there is an increasing amount of data sup-
porting early hormonal deprivation in prostate cancer
patients who are  not candidates for curative treatment,
there is no conclusive evidence for it and further ran-
domized trials are needed to verify these results and to
identify subgroups of patients who are most likely to
benefit from early hormonal manipulation.
Adjuvant Hormonal Treatment in the
Radiotherapy Setting
More reliable prospective randomized data are
available for adjuvant hormonal treatment after radio-
therapy. Bolla et al. [18] demonstrated that adjuvant
therapy with LHRH analogues starting at the beginning
of radiotherapy highly significantly improved the dis-
ease-specific and overall survival. Granfors et al. [19]
observed a significantly better 10-year survival in
patients with tumor stages T1–4N0–1 treated by radio-
therapy and orchiectomy compared with those treated
by radiotherapy alone. There was, however, mainly a
benefit for patients with lymph node metastases. No
significant difference was seen in patients without
lymph node involvement, conceivably due to the small
sample [19]. In another prospective randomized trial
published by Pilepich et al. [20], there was a signifi-
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cantly improved disease-specific survival in patients
with tumor stage C or D1 treated by adjuvant LHRH
analogues. There were, however, no differences con-
cerning overall survival with the exception of a sub-
group analysis of patients with Gleason score 8–10.
Overall, there seems to be an advantage for adjuvant
hormonal treatment after radiotherapy with curative
intent in high-risk patients with stage C or D1 prostate
cancer. [18, 20–22]. It is, however, unknown, whether
the observed survival advantage can be attributed to
hormonal therapy alone, since mainly poor-risk
patients (locally advanced disease, high Gleason score)
benefit from adjuvant androgen deprivation, whereas
in earlier stages the differences tend to diminish. It is
possible that adjuvant hormonal treatment suppresses
unnoticed micrometastatic disease which, if left
untreated, may cause rapid life-threatening tumor pro-
gression [22]. To date, studies comparing adjuvant hor-
monal therapy after radiotherapy with hormonal treat-
ment alone are lacking [23].
Adjuvant Treatment in the Radical
Prostatectomy Setting
When studies on lymph node-positive tumors [15]
are excluded, no conclusive data from randomized
studies are available on the efficacy of adjuvant treat-
ment after radical prostatectomy [9, 24]. Radiotherapy
has been investigated as adjunctive treatment in
patients with margin-positive tumors after radical
prostatectomy without demonstrable benefit [25]. In
our own controlled multicenter study, 356 patients
with pT3 disease were randomized into 2 groups: group
1 received flutamide as adjuvant treatment, and group
2 received no further treatment. In a preliminary analy-
sis, tumor progression (a PSA value of 5 ng/ml or two
PSA values of 2 ng/ml more than 3 months apart with
an increasing tendency, or three PSAvalues of 1 ng/ml
more than 3 months apart with an increasing tendency,
or clinical progression) was significantly delayed by
adjuvant treatment with flutamide (fig. 1). When, how-
ever, only clinical recurrence was considered, there was
no detectable difference, possibly due to the small num-
ber of events up to the last follow-up (flutamide group
4/139; control group 5/144; table 1) [24, 26]. At pres-
ent, a reevaluation of the study is being done, and more
mature data will soon be available. The side effects of
flutamide such as gynecomastia and nausea are consid-
erable disadvantages limiting its suitability as an adju-
vant treatment drug. In our study, nearly every 5th
Table 1. Sites and frequency of tumor progression adjuvant treat-
ment with flutamide versus the control group [26]
Total Flutamide Control
PSA increase only 23 3 20
Local progression 3 – 3
Bone metastases 3 2 1
Bone and lung metastases 1 1 –
Bone and skin metastases 1 – 1
Multiple metastases 1 1 –
Total 32 (100%) 7 (22%) 25 (78%)
Fig. 1. Tumor progression during adjuvant treatment with flu-
tamide versus the control group [26].
Fig. 2. Distribution of recruited patients over the three trials of
the Bicalutamide Early Prostate Cancer Program [27]. Total num-
ber of patients enrolled: 8,115.
navia [27]. Recruitment to the program, which began
in 1995, has been completed in 1998, and first results
will soon be available [27, 28]. It can be expected that
these trials will answer some questions about adjuvant
antiandrogenic treatment in organ-confined versus
locally advanced prostate cancer with or without radi-
cal prostatectomy.
Conclusions
Despite considerable research efforts in the field of
adjuvant treatment of prostate cancer, many questions
remain unanswered. To date, studies demonstrating
advantages for adjuvant treatment mainly showed
them for patients with lymph node metastases or for
those with a high probability of micrometastatic dis-
ease [13, 15, 18, 20, 22]. Those patients probably real-
ly need immediate treatment [15]. However, there is a
different situation in early prostate cancer, where no
randomized studies have so far been completed.
Results from ongoing trials [26–28] are eagerly awaited
to answer some of these questions. However, further
studies are needed on new prognostic markers, on the
appropriate length of adjuvant treatment, and for bet-
ter tolerated treatment regimens.
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patient discontinued flutamide treatment due to side
effects [24, 26]. With bicalutamide, an antiandrogen
with fewer side effects is now available for first line and
adjuvant treatment of prostate cancer.
Bicalutamide Early Prostate Cancer Program
In the largest currently ongoing trials on adjuvant
treatment of prostate cancer, the ‘Bicalutamide Early
Prostate Cancer Program’ (n = 8,115), the non-steroidal
antiandrogen bicalutamide is being assessed as adju-
vant therapy after primary treatment with curative
intent or as an immediate hormonal therapy in patients
with early prostate cancer (T1–4N0–1M0). The pro-
gram comprises three double-blind, parallel-group tri-
als (one in North America, one in Scandinavia and one
in a number of countries worldwide, fig. 2), all of which
enrolled and randomized patients on a 1:1 basis to
either bicalutamide 150 mg once daily or placebo [27].
In North America, more than 80% of patients enrolled
had previously undergone radical prostatectomy, com-
pared to about 60% in Europe and less than 20% in
Scandinavia. In North America, more than 70% of
patients entered had a tumor stage of less than T3, com-
pared with approximately 60% in Europe and Scandi-
References
1 Smart CR: The results of prostate carcinoma
creening in the US as reflected in the surveil-
lance, epidemiology, and end results pro-
gram. Cancer 1997;80:1835–1844.
2 Zincke H, Oesterling JE, Blute ML,
Bergstralh EJ, Myers RP, Barrett DM: Long-
term (15 years) results after radical prosta-
tectomy for clinically localized (stage T2c or
lower) prostate cancer. J Urol 1994;152:
1850–1857.
3 Gerber GS, Thisted RA, Chodak GW,
Schröder FH, Frohmüller HG, Scardino PT,
Paulson DF, Middleton AW, Rukstalis DB,
Smith JA, Ohori M, Theiss M, Schellhammer
PF: Results of radical prostatectomy in men
with locally advanced prostate cancer: Multi-
institutional pooled analysis. Eur Urol 1997;
32:385–390.
4 Bolla M: Adjuvant hormonal treatment with
radiotherapy for locally advanced prostate
can-cer. Eur Urol 1999;35(suppl 1):23–26.
5 Byar DP: VACURG studies of conservative
treatment. Scand J Urol Nephrol 1980;55
(suppl):99–102.
6 Daniell HW: Osteoporosis after orchiectomy
for prostate cancer. J Urol 1997;157:439–
444.
7 Epstein JI, Partin AW, Sauvageot J, Walsh
PC: Prediction of progression following radi-
cal prostatectomy. A multivariate analysis of
721 men with long-term follow-up. Am J Surg
Pathol 1996;20:286–292.
8 Kupelian P, Katcher J, Levin H, Zippe C,
Klein E: Correlation of clinical and patholog-
ic factors with rising prostate-specific antigen
profiles after radical prostatectomy alone for
clinically localized prostate cancer. Urology
1996;48:249–260.
9 Tyrrell CJ: Adjuvant and neoadjuvant hor-
monal therapy for prostate cancer. Eur Urol
1999;36:549–558.
10 Huggins C, Hodges CV: Studies on prostatic
cancer. I. The effect of castration, of estrogen
and of androgen injection on serum phospha-
tases in metastatic carcinoma of the prostate.
Cancer Res 1941;1:293–297.
11 Huggins C, Stevens RE, Hodges CV: Studies
on prostatic cancer. II. The effect of castra-
tion on advanced carcinoma of the prostate
gland. Arch Surg 1941;43:209–223.
12 Huggins C, Scott WW, Hodges CV: Studies
on prostatic cancer. III. The effect of fever, of
desoxycorticosterone and of estrogen on clin-
ical patients with metastatic carcinoma of the
prostate. J Urol 1941;46:997–1006.
13 Zincke H, Bergstralh EJ, Larson-Keller JJ,
Farrow GM, Myers RP, Lieber MM, Barrett
DM, Rife CC, Gonchoroff NJ: Stage D1
prostate cancer treated by radical prostatec-
tomy and adjuvant hormonal treatment.
Cancer 1992;70:311–323.
14 The Medical Research Council Prostate Can-
cer Working Party Investigators Group:
Immediate versus deferred treatment for
advanced prostatic cancer: Initial results of
the Medical Reseach Council trial. Br J Urol
1997;79:235–246.
15 Messing EM, Manola J, Sarosdy M, Wilding
G, Crawford ED, Trump D: Immediate 
hormonal therapy compared with observa-
tion after radical prostatectomy and pelvic
lymphadenectomy in men with node-positive
prostate cancer. N Engl J Med 1999;341:
1781–1788.
5Urol Int 2002;68:1–5Perspectives in Adjuvant Treatment of
Prostate Cancer
16 Eisenberger MA, Walsh PC: Early androgen
ablation for prostate cancer? N Engl J Med
1999;341:1837–1838.
17 Seay TM, Blute ML, Zincke H: Long-term
outcome in patients with pTxN+ adenocarci-
noma of prostate treated with radical prosta-
tectomy and early androgen ablation. J Urol
1998;159:357–364.
18 Bolla M, Gonzalez D, Warde P, Dubois JB,
Mirimanoff RO, Storme G, Bernier J, Kuten
A, Sternberg C, Gil T, Collette L, Pierart M: 
Improved survival in patients with locally ad-
vanced prostate cancer treated with radio-
therapy and goserelin. N Engl J Med 1997;
337:295–300.
19 Granfors T, Modig H, Damber JE, Tomic R:
Combined orchiectomy and external radio-
therapy versus radiotherapy alone for non-
metastatic prostate cancer with or without
pelvic lymph node involvement: A prospec-
tive randomized study. J Urol 1998;159:
2030–2034.
20 Pilepich MV, Caplan R, Byhardt RW, Law-
ton CA, Gallagher MJ, Mesic JB, Hanks 
GE, Coughlin CT, Porter A, Shipley WU,
Grignon D: Phase III trial of androgen sup-
pression using goserelin in unfavorable prog-
nosis carcinoma of the prostate treated with
definitive radiotherapy – Report of RTOG
protocol 85–31. J Clin Oncol 1997;15:1013–
1021.
21 Schröder FH, van den Ouden D: Manage-
ment of locally advanced prostate cancer. 2.
Radio-therapy, neoadjuvant endocrine treat-
ment, up-date 1997–1999. World J Urol
2000;18:204–215.
22 Pollack A, Zagars GK: Androgen ablation in
addition to radiation therapy for prostate
cancer: Is there a true benefit? Semin Radiat
Oncol 1998;8:95–106.
23 Lee HHK, Warde P, Jewett MAS: Neoadju-
vant hormonal therapy in carcinoma of the
prostate. BJU Int 1999;83:438–448.
24 Wirth M, Froehner M: A review of studies of
hormonal adjuvant therapy in prostate can-
cer. Eur Urol 1999;36(suppl 2):14–19.
25 Paulson DF, Moul JW, Robertson JE,
Walther PJ: Postoperative radiotherapy of
the prostate for patients undergoing radical
prostatectomy with positive margins, semi-
nal vesicle involvement and/or penetration
through the capsule. J Urol 1990;143:1178–
1182.
26 Wirth M, Frohmüller H, Marx F, for the
study group: Adjuvant antiandrogenic treat-
ment after radical prostatectomy in stage C
prostate cancer – Preliminary results of a 
randomized controlled multicenter trial
(abstract). J Urol 1997;157(suppl):1308.
27 Wirth MP, Iversen P, McLeod DG, for the
study group: Bicalutamide (‘Casodex’) early
prostate cancer program: Final demographic
data from over 8,000 randomized patients
(abstract). Eur Urol 1999;35(suppl 2):A52.
28 See WA, McLeod D, Iversen P, Wirth M: The
bicalutamide Early Prostate Cancer Program.
Demography. Urol Oncol 2001;6:43–47.
